CompletedPhase 1NCT05737485

Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects

Studying Primary ciliary dyskinesia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
ReCode Therapeutics
Principal Investigator
John Matthews, MBBS, MCRP, PhD
ReCode Therapeutics, Inc.
Intervention
RCT1100(drug)
Enrollment
9 enrolled
Eligibility
18-75 years · All sexes
Timeline
20232025

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05737485 on ClinicalTrials.gov

Other trials for Primary ciliary dyskinesia

Additional recruiting or active studies for the same condition.

See all trials for Primary ciliary dyskinesia

← Back to all trials